The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01661595 |
Recruitment Status :
Completed
First Posted : August 9, 2012
Results First Posted : July 17, 2018
Last Update Posted : July 17, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Fatigue | Drug: Sildenafil Drug: tadalafil Drug: Placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Intervention Model Description: | Subjects were assigned to one of 4 arms:
|
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue. |
Study Start Date : | November 2012 |
Actual Primary Completion Date : | June 2015 |
Actual Study Completion Date : | June 2015 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Sildenafil / Placebo
50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 0-4. Placebo for weeks 5-8.
|
Drug: Sildenafil
50 mg/day for 4 weeks
Other Names:
Drug: Placebo Placebo 1 capsule per day for four weeks. |
Active Comparator: Tadalafil / Placebo
10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 0-4. Placebo for weeks 5-8.
|
Drug: tadalafil
10 mg/day for 4 weeks.
Other Names:
Drug: Placebo Placebo 1 capsule per day for four weeks. |
Active Comparator: Placebo / Sildenafil
Placebo for weeks 0-4. 50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 5-8.
|
Drug: Sildenafil
50 mg/day for 4 weeks
Other Names:
Drug: Placebo Placebo 1 capsule per day for four weeks. |
Active Comparator: Placebo / Tadalafil
Placebo for weeks 0-4. 10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 5-8.
|
Drug: tadalafil
10 mg/day for 4 weeks.
Other Names:
Drug: Placebo Placebo 1 capsule per day for four weeks. |
- Skeletal Muscle Fatigue as Measured by Biodex 4 Pro After 4 Weeks of Placebo [ Time Frame: after 4 weeks of placebo ]Isokinetic Fatigue Measure (knee extension) is measured on a Biodex System Pro 4 within a 75 degree range of motion. Subjects performed concentric contractions at a fixed speed of 120 degree/sec. 50 contractions were performed at 100% force, one contraction every second. Isokinetic fatigue will be measured at week 4 and week 8. Depending on grouping, the week 4 and week 8 measures may be placebo or active drug. Data will be reported as after 4 weeks of placebo or after 4 weeks of active drug. Data is presented as mean maximum force over all 50 kicks.
- Skeletal Muscle Fatigue as Measured by Biodex 4 Pro After 4 Weeks of Active Drug [ Time Frame: after 4 weeks of active drug ]Isokinetic Fatigue Measure (knee extension) is measured on a Biodex System Pro 4 within a 75 degree range of motion. Subjects performed concentric contractions at a fixed speed of 120 degree/sec. 50 contractions were performed at 100% force, one contraction every second. Isokinetic fatigue will be measured at week 4 and week 8. Depending on grouping, the week 4 and week 8 measures may be placebo or active drug. Data will be reported as after 4 weeks of placebo or after 4 weeks of active drug. Data is presented as mean maximum force over all 50 kicks.
- Exercised Induced Fatigability as Measured by Fatigue Rating Scale After 4 Weeks of Placebo [ Time Frame: after 4 weeks of placebo ]The fatigue rating scale is a scale from 0 to 10 with 0 being no fatigue at all and 10 being the worst fatigue the subject can imagine. The subject is asked to rate their level of fatigue in their leg. This test was performed before and immedicately after the Biodex leg fatigue test after 4 weeks of placebo. Data is presented as change in scale from pre fatigue test to post fatigue test, with a higher score indicating a greater level of fatigue.
- Exercised Induced Fatigability as Measured by Fatigue Rating Scale After 4 Weeks of Active Drug [ Time Frame: after 4 weeks of active drug ]The fatigue rating scale is a scale from 0 to 10 with 0 being no fatigue at all and 10 being the worst fatigue the subject can imagine. The subject is asked to rate their level of fatigue in their leg. This test was performed before and immedicately after the Biodex leg fatigue test. Data is presented as change in scale from pre fatigue test to post fatigue test, with a higher score indicating a greater level of fatigue.
- Maximum Peak Isometric Leg Strength as Measured by Biodex Pro4 After 4 Weeks of Placebo [ Time Frame: after 4 weeks of placebo ]Peak isometric strength is measured on a Biodex System 4 Pro. This test is isolated to the quadricep muscle of one leg. Isometric test is performed at 90 degrees with 5 seconds of force production for each contraction and 15 seconds of rest. 1 set of 3 contractions at 100% force performed. Isometric strength was measured at week 4 and week 8. Depending on grouping, the week 4 and week 8 measures may be placebo or active drug. Data will be reported as after 4 weeks of placebo or after 4 weeks of active drug.
- Maximum Peak Isometric Leg Strength as Measured by Biodex Pro4 After 4 Weeks of Active Drug. [ Time Frame: after 4 weeks of active drug ]Peak isometric strength is measured on a Biodex System 4 Pro. This test is isolated to the quadricep muscle of one leg. Isometric test is performed at 90 degrees with 5 seconds of force production for each contraction and 15 seconds of rest. 1 set of 3 contractions at 100% force performed. Isometric strength was measured at week 4 and week 8. Depending on grouping, the week 4 and week 8 measures may be placebo or active drug. Data will be reported as after 4 weeks of placebo or after 4 weeks of active drug.
- Maximum Peak Isokinetic Leg Strength as Measured by Biodex Pro4 After 4 Weeks of Placebo. [ Time Frame: after 4 weeks of placebo ]Isokinetic strength (knee extension) is measured on a Biodex System Pro 4 within a 75 degree range of motion. Subjects performed concentric contractions at a fixed speed of 120 degree/sec. 1 set of 3 contractions were performed at 100% force. Isokinetic strength will be measured at week 4 and week 8. Depending on grouping, the week 4 and week 8 measures may be placebo or active drug. Data will be reported as after 4 weeks of placebo or after 4 weeks of active drug.
- Maximum Peak Isokinetic Leg Strength as Measured by Biodex Pro4 After 4 Weeks of Active Drug [ Time Frame: after 4 weeks of active drug ]Isokinetic strength (knee extension) is measured on a Biodex System Pro 4 within a 75 degree range of motion. Subjects performed concentric contractions at a fixed speed of 120 degree/sec. 1 set of 3 contractions were performed at 100% force. Isokinetic strength will be measured at week 4 and week 8. Depending on grouping, the week 4 and week 8 measures may be placebo or active drug. Data will be reported as after 4 weeks of placebo or after 4 weeks of active drug.
- Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry at Week 0. [ Time Frame: week 0 ]Lean Body Mass is calculated from a whole body scan measured on a dual energy x-ray absorptiometry.
- Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry at Week 4. [ Time Frame: week 4 ]Lean Body Mass is calculated from a whole body scan measured on a dual energy x-ray absorptiometry.
- Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry at Week 8. [ Time Frame: week 8 ]Lean Body Mass is calculated from a whole body scan measured on a dual energy x-ray absorptiometry.
- Fat Mass as Measured by Dual Energy X-ray Absorptiometry at Week 0. [ Time Frame: week 0 ]Fat Mass is calculated from a whole body scan measured on a dual energy x-ray absorptiometry.
- Fat Mass as Measured by Dual Energy X-ray Absorptiometry at Week 4. [ Time Frame: week 4 ]Fat Mass is calculated from a whole body scan measured on a dual energy x-ray absorptiometry.
- Fat Mass as Measured by Dual Energy X-ray Absorptiometry at Week 8. [ Time Frame: week 8 ]Fat Mass is calculated from a whole body scan measured on a dual energy x-ray absorptiometry.
- Walking Distance at 100% Effort as Measured by Walking Test After 4 Weeks of Placebo [ Time Frame: after 4 weeks of placebo ]Walking performance will be assessed during 2 minutes of walking in long corridor hallways. Subjects will be asked to walk at 100% effort (as quickly as they can safely walk without running) for 2 minutes. Distance traveled for the 2 minutes will be recorded. The walking test will be completed at week 4 and week 8. Depending on grouping, the week 4 and week 8 measures may be placebo or active drug. Data will be reported as after 4 weeks of placebo or after 4 weeks of active drug.
- Walking Distance at 100% Effort as Measured by Walking Test After 4 Weeks of Active Drug [ Time Frame: after 4 weeks of active drug ]Walking performance will be assessed during 2 minutes of walking in long corridor hallways. Subjects will be asked to walk at 100% effort (as quickly as they can safely walk without running) for 2 minutes. Distance traveled for the 2 minutes will be recorded. The walking test will be completed at week 4 and week 8. Depending on grouping, the week 4 and week 8 measures may be placebo or active drug. Data will be reported as after 4 weeks of placebo or after 4 weeks of active drug.
- Perceptual Fatigue as Measured by Multidimensional Fatigue Symptom Inventory - Short Form Total Score at Week 0 [ Time Frame: Week 0 ]Fatigue symptoms will be measured using the 30-item Multidimensional Fatigue Symptom Inventory - Short Form, a validated measure that yields one overall score of total fatigue calculated using five sub scales (general, physical, emotional, mental, vigor). With the exception of the vigor sub scale, higher scores indicate greater fatigue. Total fatigue score is calculated by summing the sub categories (general, physical, emotional and mental) and subtracting vigor. Total scores range from -24 to 96, with a higher score indicating more fatigue.
- Perceptual Fatigue as Measured by Multidimensional Fatigue Symptom Inventory - Short Form Total Score at Week 4 [ Time Frame: week 4 ]Fatigue symptoms will be measured using the 30-item Multidimensional Fatigue Symptom Inventory - Short Form, a validated measure that yields one overall score of total fatigue calculated using five sub scales (general, physical, emotional, mental, vigor). With the exception of the vigor sub scale, higher scores indicate greater fatigue. Total fatigue score is calculated by summing the sub categories (general, physical, emotional and mental) and subtracting vigor. Total scores range from -24 to 96, with a higher score indicating more fatigue.
- Perceptual Fatigue as Measured by Multidimensional Fatigue Symptom Inventory - Short Form Total Score at Week 8 [ Time Frame: week 8 ]Fatigue symptoms will be measured using the 30-item Multidimensional Fatigue Symptom Inventory - Short Form, a validated measure that yields one overall score of total fatigue calculated using five sub scales (general, physical, emotional, mental, vigor). With the exception of the vigor sub scale, higher scores indicate greater fatigue. Total fatigue score is calculated by summing the sub categories (general, physical, emotional and mental) and subtracting vigor. Total scores range from -24 to 96, with a higher score indicating more fatigue.
- Hemoglobin Level at Week 0 [ Time Frame: week 0 ]Hemoglobin was measured by University of Texas Medical Branch Clinical Laboratory. Normal ranges are 11.6 - 15.0 g/dL.
- Hemoglobin Level Measured at Week 4 [ Time Frame: week 4 ]Hemoglobin was measured by University of Texas Medical Branch Clinical Laboratory. Normal ranges are 11.6 - 15.0 g/dL.
- Hemoglobin Level Measured at Week 8 [ Time Frame: week 8 ]Hemoglobin was measured by University of Texas Medical Branch Clinical Laboratory. Normal ranges are 11.6 - 15.0 g/dL.
- Hematocrit Level Measured at Week 0 [ Time Frame: week 0 ]Hematocrit was measured by University of Texas Medical Branch Clinical Laboratory. Normal ranges are 35.7 - 45.2%.
- Hematocrit Level Was Measured at 4 Weeks [ Time Frame: 4 weeks ]Hematocrit was measured by University of Texas Medical Branch Clinical Laboratory. Normal ranges are 35.7 - 45.2%.
- Hematocrit Level Measured at Week 8 [ Time Frame: week 8 ]Hematocrit was measured by University of Texas Medical Branch Clinical Laboratory. Normal ranges are 35.7 - 45.2%.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age 50-60 years of age
- Ability to sign consent form (score>23 on the 30-item Mini Mental Status examination, MMSE)
- Stable body weight for at least three months.
Exclusion Criteria:
- Physical dependence or frailty (impairment in any of the Activities of Daily Living (ADL), history of falls (>2/year) or significant weight loss in the past year).
- Pregnancy
- Significant heart, liver, kidney, blood or respiratory disease.
- Peripheral vascular disease.
- Diabetes mellitus or other untreated endocrine disease.
- Active cancer
- Use of nitrates.
- Recent (within 6 months) treatment with anabolic steroids, or corticosteroids.
- Alcohol or drug abuse.
- Severe depression (>5 on the 15-item Geriatric Depression Scale, GDS).
- Cardiac abnormalities such as cardiac shunt or previously diagnosed pulmonary hypertension.
- Systolic blood pressure <100 or>150, diastolic blood pressure <60 or 90>. This range is smaller than the acceptable range stated in the prescribing information for sildenafil/tadalafil (90/50 and <170/110).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01661595
United States, Texas | |
University of Texas Medical Branch | |
Galveston, Texas, United States, 77555-0361 |
Principal Investigator: | Melinda Sheffield-Moore, PhD | University of Texas Medical Branch, Galveston |
Responsible Party: | The University of Texas Medical Branch, Galveston |
ClinicalTrials.gov Identifier: | NCT01661595 |
Other Study ID Numbers: |
12-153 |
First Posted: | August 9, 2012 Key Record Dates |
Results First Posted: | July 17, 2018 |
Last Update Posted: | July 17, 2018 |
Last Verified: | April 2018 |
Fatigue Fatigability Surface Electromyography (sEMG) cyclic guanosine monophosphate (cGMP) Nitric Oxide (NO) NO-cGMP Phosphodiesterase (PDE) Sildenafil |
Tadalafil Isotope Infusion Anabolism Upregulation Accelerometer Placebo Nitrosylation |
Fatigue Sildenafil Citrate Tadalafil Vasodilator Agents Phosphodiesterase 5 Inhibitors |
Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Urological Agents |